List of Excipients in Branded Drug BAQSIMI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	ACETIC ACID
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	BETADEX
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	DODECYLPHOSPHOCHOLINE
Eli Lilly and Company	BAQSIMI	glucagon	0002-6145	WATER

Last updated: September 25, 2026

BAQSIMI’s commercial differentiation is driven by its excipient-enabled nasal delivery system, not by glucagon itself. The formulation combines glucagon with betadex, dodecylphosphocholine and phosphatidylcholine to produce a single-use, needle-free rescue product. The principal opportunities are second-source excipient supply, lifecycle reformulation, geographic expansion, pediatric and institutional adoption, and competing nasal glucagon products. BAQSIMI is a small-molecule peptide drug, so biosimilar substitution is not the relevant competitive risk.

BAQSIMI Excipient Strategy, Patent Protection and Commercial Opportunities

What is BAQSIMI and how does its nasal formulation work?

BAQSIMI is a 3 mg glucagon nasal powder approved by the U.S. Food and Drug Administration in July 2019 for the treatment of severe hypoglycemia in adults and children aged four years and older with diabetes.[1]

The product is supplied in a single-use nasal device. It does not require reconstitution, injection, refrigeration or patient assembly. The product’s commercial value comes from converting glucagon, traditionally administered by injection, into a ready-to-use intranasal powder.

The labeled inactive ingredients are:

Excipient	Functional role in BAQSIMI
Betadex	Cyclodextrin-based carrier and formulation aid
Dodecylphosphocholine	Permeation-enhancing surfactant
Phosphatidylcholine	Phospholipid formulation and nasal-delivery component

The formulation is designed to deliver glucagon across the nasal mucosa despite the peptide’s low intrinsic permeability. The excipient system must balance several requirements:

• Rapid nasal dissolution
• Adequate mucosal residence time
• Protection of glucagon during storage
• Low nasal irritation
• Consistent powder dispersion
• Reliable emitted dose from a compact device
• Manufacturing reproducibility at low fill weights

The formulation is therefore more difficult to replicate than a conventional glucagon solution. A competitor must match the active ingredient, dose, physical form, excipient performance, device behavior and pharmacokinetic profile.

Which excipients are strategically important in BAQSIMI?

Betadex and cyclodextrin-based formulation design

Betadex is a cyclodextrin derivative used to improve the physical handling and delivery of poorly soluble or unstable compounds. In a nasal powder, cyclodextrin can influence:

• Glucagon dispersion
• Powder flow
• Moisture sensitivity
• Local dissolution
• Interaction between glucagon and the nasal mucosa

Cyclodextrins also create supplier and quality-control opportunities. Pharmaceutical-grade material must have controlled substitution, residual solvent, moisture, microbial and endotoxin profiles. A second-source supplier would need to demonstrate equivalent material performance, not merely chemical identity.

For excipient manufacturers, the most valuable opportunity is not generic cyclodextrin supply. It is a grade engineered for low-dose nasal powder applications with controlled particle size, low water activity and validated compatibility with glucagon.

Dodecylphosphocholine as a nasal absorption enhancer

Dodecylphosphocholine is the most strategically differentiated excipient in the product. It is a phospholipid-like surfactant that can improve mucosal permeation by interacting with the nasal epithelial barrier.

Its commercial value derives from its functional role. A substitute excipient would need to provide comparable absorption without creating unacceptable:

• Nasal irritation
• Tissue damage
• Variability in glucagon uptake
• Local toxicity
• Stability problems
• Powder-flow limitations

A competing formulation based on another surfactant, bile salt, phospholipid or mucoadhesive would likely require a new clinical and regulatory package. This creates an entry barrier even where the underlying active ingredient is not difficult to synthesize.

Phosphatidylcholine and phospholipid compatibility

Phosphatidylcholine supports the formulation’s lipid-based delivery strategy. It can affect powder cohesion, wetting, nasal distribution and interaction with dodecylphosphocholine.

The key technical issue is consistency. Phospholipid raw materials can vary by source, fatty-acid composition, oxidation level and moisture content. A commercial supplier that can offer highly controlled phosphatidylcholine with low oxidation and validated nasal compatibility may have a competitive advantage.

What regulatory exclusivity applies to BAQSIMI?

BAQSIMI received FDA approval on July 24, 2019. As a new chemical entity product, it received five years of regulatory exclusivity under the Federal Food, Drug, and Cosmetic Act. That period generally barred submission of an abbreviated new drug application relying on the BAQSIMI active ingredient until July 2024, subject to statutory exceptions.[1][2]

Regulatory exclusivity and patent protection are separate.

Protection category	BAQSIMI relevance
New chemical entity exclusivity	Five-year period beginning at approval
Orphan-drug exclusivity	Not the principal protection associated with BAQSIMI
Pediatric exclusivity	No separate six-month extension should be assumed without a confirmed FDA grant
Formulation patents	Potentially cover nasal powder composition, excipient ratios and delivery performance
Device patents	May cover the single-use nasal dispenser
Method-of-use patents	May cover treatment of severe hypoglycemia or administration instructions
Manufacturing patents	May cover powder processing, blending, filling and device assembly

The five-year regulatory exclusivity period is no longer the primary barrier to a new entrant. The commercial question has shifted to whether a competitor can obtain approval with a substitutable nasal glucagon product while avoiding enforceable formulation, device and method-of-use claims.

What patents protect BAQSIMI?

BAQSIMI protection is expected to rely on a layered estate rather than on glucagon composition-of-matter protection. Glucagon is an established peptide, so the strongest practical protection is likely to arise from the delivery system.

The relevant patent categories are:

1. Intranasal glucagon compositions containing a permeation enhancer.
2. Cyclodextrin-containing glucagon powder formulations.
3. Phospholipid or surfactant combinations.
4. Dry-powder manufacturing and particle-engineering methods.
5. Single-use nasal delivery devices.
6. Treatment methods using a defined intranasal glucagon dose.
7. Stability and packaging configurations.

An Orange Book analysis should distinguish between patents listed by the approved product sponsor and patents that are commercially relevant but not listed. Device and manufacturing patents may not always create the same ANDA litigation pathway as patents that directly claim the approved drug product.

How strong is the BAQSIMI patent estate?

The estate is commercially stronger than a simple glucagon patent because a successful entrant would need to solve several technical problems at the same time:

• Deliver glucagon through the nasal mucosa.
• Maintain potency in a dry powder.
• Produce a reproducible low-dose blend.
• Achieve a consistent emitted dose.
• Package the powder against moisture.
• Operate a reliable single-use device.

Its strength is weaker against a materially different nasal formulation. A competitor could pursue a different permeation enhancer, a liquid nasal spray, a higher-dose powder, or a new device. That strategy could reduce infringement exposure but would increase formulation and clinical-development costs.

Are there Paragraph IV challenges to BAQSIMI?

A conventional ANDA challenge is less straightforward for a nasal powder than for an oral tablet or injectable solution. An applicant would need to establish equivalence across the drug substance, formulation, device and delivery performance.

Potential Paragraph IV targets could include:

• Listed composition patents
• Nasal delivery patents
• Device patents
• Method-of-use claims
• Manufacturing claims relevant to the approved product

A Paragraph IV applicant could argue that listed claims are invalid, unenforceable or not infringed. It could also pursue a different formulation under a 505(b)(2) application rather than seek full ANDA substitution.

No biosimilar pathway applies. Glucagon is a peptide drug, but BAQSIMI is regulated as a drug product, not as a reference biologic eligible for biosimilar approval under the Public Health Service Act.

When does BAQSIMI lose exclusivity?

BAQSIMI’s five-year new-chemical-entity exclusivity began on July 24, 2019 and ended in July 2024. Patent expiry dates depend on the specific listed patents, terminal disclaimers, patent-term adjustments and any litigation-related changes.

The practical loss-of-exclusivity timeline is therefore:

Period	Commercial significance
2019 to July 2024	NCE exclusivity restricted standard ANDA reliance on the product
From July 2024	ANDA or 505(b)(2) development became more feasible, subject to patent barriers
Post-launch competitor period	Device, formulation, clinical and manufacturing differentiation determine substitution risk
Patent expiry period	Direct generic or authorized-competition risk increases if key claims expire or are invalidated

A generic launch would not necessarily follow immediately after regulatory exclusivity. Nasal glucagon requires specialized development, and an entrant may need a new clinical program if it cannot establish the required equivalence through an ANDA.

Who owns BAQSIMI and what licensing deal affects the product?

Eli Lilly developed and commercialized BAQSIMI before transferring the product to Amphastar Pharmaceuticals. Amphastar agreed to acquire BAQSIMI from Lilly for approximately $800 million in cash, with the transaction announced in 2023 and completed later that year.[3][4]

The transaction changed the commercial incentives around the product:

• Lilly exited direct commercialization of BAQSIMI.
• Amphastar obtained an established rescue product with an existing prescriber base.
• Amphastar added a non-injectable glucagon product to its injectable and emergency-medicine portfolio.
• Excipient sourcing, device supply and manufacturing efficiency became more important to margin protection.
• Amphastar gained an opportunity to expand distribution outside Lilly’s historical commercial channels.

The deal also makes supply-chain control strategically important. A single-source excipient or device component could expose the product to manufacturing interruptions and regulatory change-control burdens.

What commercial opportunities exist for BAQSIMI excipients?

Second-source supply

The clearest near-term opportunity is qualified second-source supply for:

• Betadex
• Dodecylphosphocholine
• Phosphatidylcholine
• Moisture-barrier packaging
• Nasal device components

Second sourcing can reduce cost and supply risk, but the supplier must support regulatory comparability. Changes in particle size, moisture, purity, oxidation and surface chemistry can affect delivered dose and nasal absorption.

Excipient grade optimization

A supplier could develop a purpose-built nasal grade with:

• Narrow particle-size distribution
• Controlled bulk density
• Low hygroscopicity
• Low endotoxin burden
• Defined phospholipid composition
• Improved powder flow
• Reduced electrostatic charging
• Long-term stability under humidity stress

Such a product could be positioned as a functional excipient platform rather than a commodity ingredient.

Reformulated nasal glucagon

A competing or next-generation formulation could target:

• Lower dose
• Faster onset
• Better stability in hot and humid climates
• Reduced nasal irritation
• Smaller device
• Improved pediatric usability
• Lower manufacturing cost

The regulatory route could be an ANDA if the product can demonstrate the required equivalence. A materially different excipient system would more likely require a 505(b)(2) application with additional clinical evidence.

Geographic expansion

The needle-free format is commercially attractive in regions where emergency glucagon training is limited. Potential channels include:

• Schools
• Pharmacies
• Ambulance services
• Sports facilities
• Diabetes clinics
• Military and occupational-health programs
• Household emergency kits

International expansion depends on country-specific nasal-device requirements, glucagon classification, excipient acceptability and reimbursement.

Institutional procurement

Hospitals and schools may value BAQSIMI because it reduces administration steps. Institutional buyers can also create demand for bundled training, emergency kits and recurring replacement programs. The main obstacles are expiration management, formulary placement and reimbursement.

How does BAQSIMI compare with competing glucagon products?

Product	Route	Device burden	Main competitive attribute
BAQSIMI	Intranasal powder	Low	Needle-free, single-use administration
Gvoke HypoPen	Subcutaneous autoinjector	Moderate	Ready-to-use injection
Zegalogue	Subcutaneous autoinjector or syringe	Moderate	Ready-to-use injectable glucagon
Traditional glucagon kits	Injection after reconstitution	High	Established, lower-cost presentation

BAQSIMI’s principal advantage is administration simplicity. Injectable products can offer mature manufacturing and potentially lower acquisition cost, but they require needle handling and more training.

The main threat is not a biosimilar. It is a competing rescue product that delivers comparable speed and reliability through a different device or nasal formulation.

What generic launch risks exist for BAQSIMI?

Base-case launch scenario

The most likely near-term competitive route is a 505(b)(2) product or a differentiated nasal glucagon product. This approach can avoid direct duplication of the BAQSIMI formulation but requires clinical and regulatory investment.

High-impact launch scenario

A successful ANDA applicant could create pharmacy-level substitution if it demonstrates equivalence and avoids enforceable listed patents. That would place pressure on:

• Net price
• Formulary access
• Pharmacy substitution
• Wholesale discounts
• Public-sector contracts
• Excipient and device costs

Delayed-launch scenario

A competitor may obtain approval but delay launch because of device manufacturing constraints, limited reimbursement, litigation, or insufficient commercial scale. Nasal-device production is a more specialized capability than conventional tablet manufacturing.

What manufacturing and IP barriers protect BAQSIMI?

The most important barriers are technical rather than ingredient scarcity.

A credible competitor needs:

1. A stable glucagon dry-powder process.
2. A validated blending method that prevents dose segregation.
3. Controlled humidity during filling.
4. A high-performance moisture-barrier container.
5. A reliable single-use nasal actuator.
6. Analytical methods for emitted dose and particle-size distribution.
7. Nasal tolerability and pharmacokinetic data.
8. Regulatory control over excipient changes.

The combination of formulation, device and process controls makes BAQSIMI more defensible than an ordinary glucagon formulation. It also creates licensing opportunities for excipient suppliers with specialized nasal-delivery technology.

Key Takeaways

• BAQSIMI is a 3 mg intranasal glucagon powder approved by FDA in 2019.
• Its core excipient system contains betadex, dodecylphosphocholine and phosphatidylcholine.
• Dodecylphosphocholine is the most strategically important functional excipient because it supports nasal permeation.
• BAQSIMI’s five-year new-chemical-entity exclusivity ended in July 2024.
• The main remaining barriers are formulation, device, manufacturing and method-of-use rights.
• Biosimilar competition is not the relevant risk; generic and 505(b)(2) competition is.
• Amphastar’s acquisition of BAQSIMI from Lilly for approximately $800 million created a new commercial platform for lifecycle management and international expansion.
• The strongest excipient opportunities are second sourcing, nasal-grade optimization and reformulated glucagon delivery systems.
• Commercial expansion is most attractive in schools, emergency medicine, pharmacies and diabetes-care channels.
• A competing product must match not only glucagon exposure, but also powder handling, device performance, stability and usability.

FAQs

Is dodecylphosphocholine unique to BAQSIMI?

No. Its strategic value comes from its function and use in the specific nasal glucagon formulation. A competitor could use another permeation enhancer, but that approach would require separate formulation, safety and regulatory development.

Can an excipient supplier sell an equivalent BAQSIMI formulation?

Not automatically. Supplying the same excipients does not authorize manufacture or sale of the finished drug. The supplier would need to address formulation rights, manufacturing controls, regulatory approval and potential patent claims.

Is BAQSIMI considered a biologic drug?

No. BAQSIMI is regulated as a drug product containing glucagon. It is not a reference biologic for purposes of the U.S. biosimilar pathway.

Could a generic company copy BAQSIMI without copying its excipients?

Potentially. A competitor could pursue a different excipient system through a distinct formulation strategy, but it would need to demonstrate comparable performance and address formulation, device and method-of-use patent risks.

What is the largest commercial opportunity for BAQSIMI?

The largest opportunity is broader adoption of ready-to-use glucagon in settings where injection training limits treatment. Schools, caregivers, pharmacies, emergency responders and international diabetes programs are the most relevant channels.

References

1. U.S. Food and Drug Administration. (2019). BAQSIMI (glucagon) nasal powder prescribing information. FDA.

2. U.S. Food and Drug Administration. (2019). BAQSIMI approval letter and Drugs@FDA records. FDA.

3. Eli Lilly and Company. (2023). Lilly to sell BAQSIMI glucagon nasal powder to Amphastar Pharmaceuticals. Lilly investor and corporate communications.

4. Amphastar Pharmaceuticals, Inc. (2023). Amphastar Pharmaceuticals completes acquisition of BAQSIMI from Eli Lilly and Company. Amphastar Pharmaceuticals.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.